Serum HER-2/neu levels in clinical studies with lapatinib in HER-2/neu positive breast cancer

被引：0
|
作者：
Maltzman, J. [1 ]
Blackwell, K. [2 ]
Stein, S. [1 ]
Martin, A. [1 ]
Westland, R. [1 ]
Burstein, H. [3 ]
Gomez, H. [4 ]
Gartner, N. [2 ]
Platek, G. [2 ]
Newmiller, M. [2 ]
Lipton, A. [5 ]
Carney, W. P. [6 ]
机构：
[1] GlaxoSmithKline Inc, Collegeville, PA USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Inst Nacl Enfermedades Neoplas, Lima, Peru
[5] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
[6] Siemens Healthcare Diagnost, Oncogene Sci Grp, Cambridge, MA USA
来源：
CLINICAL CHEMISTRY | 2008年 / 54卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
C95
引用
收藏
页码：A130 / A130
页数：1
相关论文
共 50 条
  • [31] Heterogeneity of HER-2/NEU (neu) amplification and overexpression in breast cancer.
    Axiotis, CA
    Flom, K
    LABORATORY INVESTIGATION, 1997, 76 (01) : 118 - 118
  • [32] An early decrease in serum HER-2/neu levels after initiation of primary chemotherapy for HER-2 positive breast cancer indicates response to treatment.
    Mazouni, C.
    Hall, A.
    Anderson, K.
    Peintinger, F.
    Frische, H.
    Andre, F.
    Yekell, S.
    Arun, B.
    Buzdar, A. U.
    Esteva, F.
    Pusztai, L.
    Cristofanilli, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S51 - S51
  • [33] HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
    Reilly, RT
    Gottlieb, MBC
    Ercolini, AM
    Machiels, JPH
    Kane, CE
    Okoye, FI
    Muller, WJ
    Dixon, KH
    Jaffee, EM
    CANCER RESEARCH, 2000, 60 (13) : 3569 - 3576
  • [34] Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification
    Lal, P
    Salazar, PA
    Ladanyi, M
    Chen, BY
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2003, 5 (03): : 155 - 159
  • [35] Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry:: an interlaboratory study assessing the reproducibility of HER-2/NEU testing
    Gancberg, D
    Järvinen, T
    di Leo, A
    Rouas, G
    Cardoso, F
    Paesmans, M
    Verhest, A
    Piccart, MJ
    Isola, J
    Larsimont, D
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 74 (02) : 113 - 120
  • [36] Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer
    Mary L. Disis
    Keith L. Knutson
    Kathy Schiffman
    Kristine Rinn
    Douglas G. McNeel
    Breast Cancer Research and Treatment, 2000, 62 : 245 - 252
  • [37] Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer
    Disis, ML
    Knutson, KL
    Schiffman, K
    Rinn, K
    McNeel, DG
    BREAST CANCER RESEARCH AND TREATMENT, 2000, 62 (03) : 245 - 252
  • [38] Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing
    David Gancberg
    Tero Järvinen
    Angelo di Leo
    Ghizlane Rouas
    Fatima Cardoso
    Marianne Paesmans
    Alain Verhest
    Martine J. Piccart
    Jorma Isola
    Denis Larsimont
    Breast Cancer Research and Treatment, 2002, 74 : 113 - 120
  • [39] Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer
    Gonzalez-Angulo, Ana M.
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    ONCOLOGIST, 2006, 11 (08): : 857 - 867
  • [40] Multiple Subtypes of HER-2/Neu-Positive Metastatic Breast Cancer
    Lipton, A.
    Leitzel, K.
    Koestler, W.
    Fuchs, E-M
    Singer, C. F.
    Ali, S. M.
    Huang, W.
    Sperinde, J.
    Goodman, L.
    Jin, X.
    Barerjee, J.
    Weston, J.
    Mukherjee, A.
    Larson, J.
    Weidler, J.
    Paquet, A.
    Williams, S.
    Winslow, J.
    Parry, G.
    Bates, M.
    CANCER RESEARCH, 2009, 69 (24) : 601S - 602S
12345